Combination Antibiotic Therapy for Infective Endocarditis
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Despite the availability of new and potent antibiotics, modern echocardiography, and advanced surgical techniques, infective endocarditis (IE) is still associated with high morbidity and mortality rates. Use of synergistic antibiotic combinations is an appealing way to optimize therapy for IE. This review focuses on evidence-based recommendations for combination antimicrobial therapy for IE due to the most common etiologic pathogens. Few proven synergistic approaches for the treatment of IE have been globally demonstrated via in vitro models, experimental IE models, and human clinical trials, except for IE due to enterococci. Novel approaches, such as short-course aminoglycoside therapy and double-beta-lactam combination therapy, appear to be promising for treatment of enterococcal IE. Short-course combination therapy involving agents with activity against the cell wall (CWAs) and aminoglycosides is highly effective for IE caused by viridans group streptococci. Although synergistic combination therapy with CWAs-aminoglycosides remains widely used by clinicians for Staphylococcus aureus IE, few definitive human data exist that demonstrate the clinical benefit of such an approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wilson, W. R. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530210060032 · Cited by 492
KORZENIOWSKI, O., & SANDE, M. A. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-97-4-496 · Cited by 355 · cited 2×
“In nonaddicts with left- sided IE due to S. aureus, Korzeniowski and Sande [33] reported a more rapid clearance of bacteremia but a higher rate of ne- phrotoxicity, without a reduction in mortality in the combi- nation therapy group (nafcillin and gentamicin) versus the naf- cillin-alone group.”
Heldman, A. W., Hartert, T. V., Ray, S. C., Daoud, E. G., Kowalski, T. E., Pompili, V. J., Sisson, S. D., Tidmore, W. C., vom Eigen, K. A., Goodman, S. N., et al. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(96)00070-8 · Cited by 289
Sexton, D. J., Tenenbaum, M. J., Wilson, W. R., Steckelberg, J. M., Tice, A. D., Gilbert, D., Dismukes, W., Drew, R. H., Durack, D. T., & Endocarditis Treatment Consortium Group (1998) · Clinical Infectious Diseases · doi:10.1086/515038 · Cited by 195
Ribera, E., Gomez-Jimenez, J., Cortes, E., del Valle, O., Planes, A., Gonzalez-Alujas, M. T., Almirante, B., Ocana, I., & Pahissa, A. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-12-199612150-00005 · Cited by 187
Dworkin, R. J., Sande, M. A., Lee, B. L., & Chambers, H. F. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91083-0 · Cited by 170 · cited 2×
“Subsequent studies from San Francisco General Hospital (California) confirmed the excellent efficacy of 2-week courses of nafcillin plus tobramycin, as well as 4-week courses of predominantly orally administered ciprofloxacin plus rifampin, for treatment of right-side IE due to S. aureus [ 36 , 37].”
BackgroundEnterococcal Endocarditis in Sweden, 1995–1999: Can Shorter Therapy with Aminoglycosides Be Used?
Olaison, L., Schadewitz, K., & Swedish Society of Infectious Diseases Quality Assurance Study Group for Endocarditis (2002) · Clinical Infectious Diseases · doi:10.1086/338233 · Cited by 166 · cited 3×
“Recently, Olaison and Schadewitz [41] conducted a 5-year (1995–1999) nationwide prospective study in Sweden in which 881 definite episodes of IE were identified, 93 (11”
BackgroundInfluentialTreatment of Streptomycin-Susceptible and Streptomycin-Resistant Enterococcal Endocarditis
WILSON, W. R., WILKOWSKE, C. J., WRIGHT, A. J., SANDE, M. A., & GERACI, J. E. (1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-100-6-816 · Cited by 159 · cited 1×
“There is a close correlation between enterococcal susceptibility or resistance to aminoglycosides in vitro with the following outcomes: in vitro bactericidal synergy in combination with penicillin or ampicillin; microbiologic efficacy in experimental enterococcal IE; and clinical outcome in clinical enterococcal IE [2…”
BackgroundMandell, G. L. (1970) · Archives of Internal Medicine · doi:10.1001/archinte.1970.00310020064005 · Cited by 138
Gavaldà, J., Torres, C., Tenorio, C., López, P., Zaragoza, M., Capdevila, J. A., Almirante, B., Ruiz, F., Borrell, N., Gomis, X., et al. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.3.639 · Cited by 134 · cited 3×
“Recent data have demonstrated the potential for in vitro and in vivo synergy against enterococci with combinations of thirdgeneration cephalosporins and ampicillin on the basis of global saturation of distinct penicillin-binding proteins (PBPs; see the Enterococci section below) [10–12].”
BackgroundInfluential
Cited by
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Self-citationBaddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Bolger, A. F., Levison, M. E., Ferrieri, P., Gerber, M. A., Tani, L. Y., Gewitz, M. H., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.165564 · Cited by 1,707
Self-citationManagement of infective endocarditis: challenges and perspectives
Thuny, F., Grisoli, D., Collart, F., Habib, G., & Raoult, D. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60755-1 · Cited by 437
Management Considerations in Infective Endocarditis: A Review
Wang, A., Gaca, J. G., & Chu, V. H. (2018) · JAMA · doi:10.1001/jama.2018.7596 · Cited by 368
Mechanisms of Antibiotic Resistance in Staphylococcus Aureus
Pantosti, A., Sanchini, A., & Monaco, M. (2007) · Future Microbiology · doi:10.2217/17460913.2.3.323 · Cited by 348
Jacqueline, C., Navas, D., Batard, E., Miegeville, A.-F., Le Mabecque, V., Kergueris, M.-F., Bugnon, D., Potel, G., & Caillon, J. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.1.45-51.2005 · Cited by 95
Bacteriological outcome of combination versus single-agent treatment for staphylococcal endocarditis
Drinkovic, D. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg440 · Cited by 59
Fujitani, S., Rowlinson, M., & George, W. L. (2008) · Clinical Infectious Diseases · doi:10.1086/529199 · Cited by 24
Synergie et antagonisme en antibiothérapie
Denes, É., & Hidri, N. (2009) · Antibiotiques · doi:10.1016/j.antib.2009.02.001 · Cited by 12
Metadata
- Authors
- Le, T., & Bayer, A. S.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-03
- Volume
- 36
- Issue
- 5
- Pages
- 615-621
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2143877431
- Cited by
- 117
- References
- 12
- FWCI
- 8.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.